CompletedNCT04982029
Cannabidiol and reward and stress processing during opioid treatment
About this title
Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
Read the official source — NCT04982029Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Boston and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: April 14, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 15
- Sponsor
- Brigham and Women's Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04982029
- Official title
Show the full official title
Cannabidiol on reward-and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder: A Double-blind, Placebo-controlled, Cross-over Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston · Rutland
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Brigham and Women's Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Cannabidiol 100 MG/ML [Epidiolex] and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
